BioCentury | Aug 8, 2018
Distillery Therapeutics

Cardiovascular

...with normal expression. Next steps could include testing CD29 inhibitors in additional models of endotoxemia. OncoSynergy Inc....
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Integrin β1 (CD29); c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)

...scrambled siRNA. Next steps include testing CD29 inhibitors in animal models of other c-MET-driven cancers. OncoSynergy Inc....
BioCentury | Jun 16, 2014
Emerging Company Profile

OncoSynergy: Detoxing its target

...protein would be prohibitively toxic because of its essential role in normal cellular signaling processes. OncoSynergy Inc....
...of skin and gastrointestinal bleeding - because of its role in normal intercellular signaling processes. OncoSynergy's...
...the technology into OncoSynergy in 2011. In a study published in Cancer Research last year, OncoSynergy...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...low-dose Avastin decreased tumor growth compared with low-dose Avastin plus control IgG. Ongoing work by OncoSynergy Inc....
...online May 23, 2013 Patented by The Regents of the University of California; licensed to OncoSynergy...
...May 3, 2013; doi:10.1158/0008-5472.CAN-13-0011 Contact: W. Shawn Carbonell, University of California, San Francisco, Calif. e-mail: shawn@oncosynergy.com BC...
Items per page:
1 - 4 of 4
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cardiovascular

...with normal expression. Next steps could include testing CD29 inhibitors in additional models of endotoxemia. OncoSynergy Inc....
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Integrin β1 (CD29); c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)

...scrambled siRNA. Next steps include testing CD29 inhibitors in animal models of other c-MET-driven cancers. OncoSynergy Inc....
BioCentury | Jun 16, 2014
Emerging Company Profile

OncoSynergy: Detoxing its target

...protein would be prohibitively toxic because of its essential role in normal cellular signaling processes. OncoSynergy Inc....
...of skin and gastrointestinal bleeding - because of its role in normal intercellular signaling processes. OncoSynergy's...
...the technology into OncoSynergy in 2011. In a study published in Cancer Research last year, OncoSynergy...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Cancer

...low-dose Avastin decreased tumor growth compared with low-dose Avastin plus control IgG. Ongoing work by OncoSynergy Inc....
...online May 23, 2013 Patented by The Regents of the University of California; licensed to OncoSynergy...
...May 3, 2013; doi:10.1158/0008-5472.CAN-13-0011 Contact: W. Shawn Carbonell, University of California, San Francisco, Calif. e-mail: shawn@oncosynergy.com BC...
Items per page:
1 - 4 of 4